Amarin Corp Plc (AMRN)

[HDGabor]

con’t:

Based on FDA' logic I changed my mind and I think we have to stop Reduce-IT (however it will be successful), since it will not provide enough evidence relevant to the specific Vascepa coadministration indication to warrant grant of the indication, however R-IT demonstrated unequivocally additional cardiovascular benefit from non-statin lipid-modulating drugs, so FDA will allow the indication for other non-statin lipid-modulating drugs (ie.: Lovaza and Epanova), but not for Vascepa ……